The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Xiao-Jun Ma
Project Title: NULISA BD-pTau217 Assay Development
Date: February 20, 2026 at 12:20 pm
Request ID: T2608
Aim 1: To evaluate and establish clinical performance of the BD-pTau217 assay.
Aim 2:
Aim 3:
Aim 4:
Investigator: Julio C. Rojas
Project Title: Clinical associations of CSF MMP10 in Pick’s disease
Date: February 17, 2026 at 7:27 pm
Request ID: T2607
Aim 1: Determine the CSF aptamer-proteomics (SomaScan v4.0) signature of FTLD-tau Pick’s disease (n = 30) in contrast to other FTLD subtypes (n = 30), MAPT mutation carriers (n = 20), biomarker-confirmed Alzheimer’s disease (n = 30) and healthy controls (n = 30).
Aim 2: Quantify CSF MMP10 in FTLD-tau Pick’s disease (n = 30) with ultrasensitive electrochemiluminescence-based and proximity extension immunoassays and compare with CSF levels in other FTLD subtypes (n = 30), MAPT mutation carriers (n = 20), biomarker-confirmed Alzheimer’s disease (n = 30) and controls.
Aim 3: Determine the diagnostic performance, and associations with clinical measures of of disease severity of CSF MMP10 in Pick’s disease and other FTLD subtypes, Alzheimer’s disease and controls.
Aim 4:
Investigator: Ana Pereira, MD
Project Title: Synaptic Tau and Lewy Body Co-Pathology in Alzheimer’s Disease: Sex-Specific Mechanisms and Biomarker Discovery
Date: February 14, 2026 at 2:57 pm
Request ID: T2606
Aim 1: Examine sex differences in synaptic Tau seeding and their relationship to cognitive decline in AD, considering LB co-pathology.
Aim 2: Define sex- and LB-specific molecular signatures in the synaptic proteome associated with Tau pathology and cognitive decline in AD
Aim 3:
Aim 4:
Investigator: Laura Campisi
Project Title: Analysis of CD8 T Cell Localization in Human ALS
Date: February 13, 2026 at 3:00 pm
Request ID: T2605
Aim 1: To examine the presence and spatial distribution of CD8 T cells in the precentral gyrus and other regions of the corticospinal tract from cases with minimal pathology and to compare these findings with ALS cases
Aim 2:
Aim 3:
Aim 4:
Investigator: Sebastian Palmqvist
Project Title: Plasma P-tau217 and cognitive progression in Adults with Unimpaired Cognition: A Multi-National, Non-Interventional Cohort Study
Date: February 13, 2026 at 12:20 pm
Request ID: T2604
Aim 1: To estimate the cumulative incidence and annual incidence rate of cognitive impairment during longitudinal follow-up in cognitively unimpaired adults
Aim 2: To compare the unadjusted and adjusted cumulative incidence and annual incidence rate of cognitive impairment during longitudinal follow-up in cognitively unimpaired adults between plasma P-tau217 categories (e.g., positive vs. negative) and across P-tau217 quartiles or deciles at the index date
Aim 3:
Aim 4:
Investigator: Suzanne Schindler
Project Title: Alzheimer’s Disease Blood-Based Biosignature for Predicting Clinical Progression
Date: February 4, 2026 at 9:06 am
Request ID: T2603
Aim 1: Generate and validate a biosignature for: Cognitively unimpaired individuals (CU) who progress to mild cognitive impairment (MCI) at 24 months based on a contrast between two groups: CU individuals who remain cognitively unimpaired at 24 months CU individuals who progress to MCI at 24 month
Aim 2: Generate and validate a biosignature for: Individuals with MCI who progress to dementia at 24 months based on a contrast between two groups: Individuals with MCI who remain classified as MCI at 24 months Individuals with MCI who progress to dementia at 24 months
Aim 3: To evaluate the association between baseline biomarkers and magnitude of cognitive and functional decline.
Aim 4:
Investigator: Susan Acton
Project Title: Pilot method development for characterization of LPAR3 expression in the Alzheimer’s Brain
Date: February 2, 2026 at 8:10 am
Request ID: T2602
Aim 1: Establish LPAR3 staining methods for brains preserved by the Knight-ADRC
Aim 2: Determine where LPAR3 is expressed in the hippocampus and frontal cortex in minimal pathology controls and high/intermediate AD pathology
Aim 3:
Aim 4:
Investigator: Soumya Mukherjee
Project Title: Distribution of big tau isoform across CNS and PNS, and of Aβ, ApoE and tau PTMs across multiple brain regions
Date: January 18, 2026 at 11:53 am
Request ID: T2601
Aim 1: Measure tau (small and big tau) and Aβ isoforms across multiple brain regions
Aim 2: Measure Aβ, ApoE and tau PTMs across multiple brain regions
Aim 3:
Aim 4:
Investigator: Jessica Mozersky & Sarah Hartz
Project Title: Evaluation of plasma phosphorylated tau in the Knight ADRC cohort
Date: January 8, 2026 at 7:36 pm
Request ID: T2515-A
Aim 1: Compare & map plasma p-tau 217% measures from the Bateman lab to plasma p-tau 217% those from C2N
Aim 2:
Aim 3:
Aim 4:
Investigator: Andrew Yoo
Project Title: Modeling Neuronal Aging and Alzheimer’s Disease via 3D Direct Reprograming of Patient Fibroblast
Date: January 7, 2026 at 5:20 pm
Request ID: T2508-A
Aim 1: Testing the effect of SORL1 variants on APP processing in directly reprogrammed human neurons
Aim 2:
Aim 3:
Aim 4: